Invokamet Approval History
FDA Approved: Yes (First approved August 8, 2014)
Brand name: Invokamet
Generic name: canagliflozin and metformin
Dosage form: Tablets
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction
Invokamet (canagliflozin/metformin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination indicated for the treatment of type 2 diabetes, and to reduce the risk of cardiovascular events (including heart attack, stroke or death) in adults with type 2 diabetes and established cardiovascular disease.
Development History and FDA Approval Process for Invokamet
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.